Trials / Conditions / Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

23 registered clinical trials studyying Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — 10 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minoritie NCT06859008	City of Hope Medical Center	Phase 1
Recruiting	A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) NCT07154264	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	Phase 2
Recruiting	A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) NCT07139873	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	Phase 3
Recruiting	LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of NCT06978088	Zulfa Omer	Phase 2
Recruiting	Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT06757647	Seema Bhat	Phase 2
Recruiting	DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) NCT06539182	Dizal Pharmaceuticals	Phase 2
Not Yet Recruiting	(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) NCT05923502	Ruijin Hospital	—
Recruiting	The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia NCT05876923	Mayo Clinic	N/A
Recruiting	Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors NCT05643235	Northwell Health	N/A
Recruiting	Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted P NCT05294731	BeiGene	Phase 1 / Phase 2
Unknown	Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL NCT05322733	The First Affiliated Hospital with Nanjing Medical University	Phase 2
Unknown	PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies NCT05003141	Qilu Puget Sound Biotherapeutics (dba Sound Biologics)	Phase 1
Active Not Recruiting	Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic NCT04657094	City of Hope Medical Center	Phase 2
Completed	Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With He NCT04748185	Mayo Clinic	—
Withdrawn	Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 201 NCT04665115	Academic and Community Cancer Research United	Phase 2
Completed	Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia NCT05007860	Massachusetts General Hospital	—
Active Not Recruiting	Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lym NCT04458610	M.D. Anderson Cancer Center	Phase 2
Completed	Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyr NCT04116437	BeiGene	Phase 2
Completed	High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in P NCT03128359	City of Hope Medical Center	Phase 2
Completed	Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lympho NCT03041636	M.D. Anderson Cancer Center	Phase 2
Completed	Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma NCT02652715	Mayo Clinic	N/A
Completed	A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL NCT02268851	Dana-Farber Cancer Institute	Phase 1
Completed	Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00090090	Spectrum Pharmaceuticals, Inc	Phase 2